The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S3-S9 , May 2006

Risk Constellations in Patients with the Metabolic Syndrome: Epidemiology, Diagnosis, and Treatment Patterns

  • Steven M. Haffner, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Steven M. Haffner, MD, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900.

References 

  1. Wild S , Roglic G , Green A , et al.   Global prevalence of diabetes (estimates for the year 2000 and projections for 2030) . Diabetes Care . 2004;27:1047–1053
  2. Haffner SM , Lehto S , Ronnemaa T , et al.   Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med . 1998;339:229–234
  3. Stratton IM , Adler AI , Neil HA , et al.   Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) (prospective observational study) . BMJ . 2000;321:405–412
  4. Adler AI , Stratton IM , Neil HA , et al.   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36) (prospective observational study) . BMJ . 2000;321:412–419
  5. Haffner SM , Stern MP , Hazuda HP , et al.   Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? . JAMA . 1990;263:2893–2898
  6. Hu FB , Stampfer MJ , Haffner SM , et al.   Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes . Diabetes Care . 2002;25:1129–1134
  7. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA . 2001;285:2486–2497
  8. Alberti KGMM , Zimmet PZ . Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation . Diabet Med . 1998;15:539–553
  9. Alberti K , George MM , Zimmet P , et al.   The metabolic syndrome—a new worldwide definition . Lancet . 2005;366:1059–1062
  10. Ford ES , Giles WH , Dietz WH . Prevalence of the metabolic syndrome among US adults (findings from the third National Health and Nutrition Examination Survey) . JAMA . 2002;287:356–359
  11. Festa A , D’Agostino R , Howard G , et al.   Chronic subclinical inflammation as part of the insulin resistance syndrome (the Insulin Resistance Atherosclerosis Study (IRAS)) . Circulation . 2000;102:42–47
  12. Lakka HM , Laaksonen DE , Lakka TA , et al.   The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men . JAMA . 2002;288:2709–2716
  13. Alexander CM , Landsman PB , Teutsch SM , Haffner SM . NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older . Diabetes . 2003;52:1210–1214
  14. Hunt KJ , Resendez RG , Williams K , et al.   National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study . Circulation . 2004;110:1251–1257
  15. Lorenzo C , Okoloise M , Williams K , et al.   The metabolic syndrome as predictor of type 2 diabetes (the San Antonio Heart Study) . Diabetes Care . 2003;26:3153–3159
  16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the diagnosis and classification of diabetes mellitus . Diabetes Care . 2003;26(suppl 1):S5–S10
  17. Simpson RW , Shaw JE , Zimmet PZ . The prevention of type 2 diabetes—lifestyle change or pharmacotherapy? A challenge for the 21st century . Diabetes Res Clin Pract . 2003;59:165–180
  18. Knowler WC , Barrett-Connor E , Fowler SE , et al.   Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med . 2002;346:393–403
  19. Chiasson JL , Josse RG , Gomis R , et al.   Acarbose for prevention of type 2 diabetes mellitus (the STOP-NIDDM randomised trial) . Lancet . 2002;359:2072–2077
  20. Buchanan TA , Xiang AH , Peters RK , et al.   Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women . Diabetes . 2002;51:2796–2803
  21. Pan XR , Li GW , Hu YH , et al.   Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance (the Da Qing IGT and Diabetes Study) . Diabetes Care . 1997;20:537–544
  22. Tuomilehto J , Lindstrom J , Eriksson JG , et al.   Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance . N Engl J Med . 2001;344:1343–1350
  23. West of Scotland Coronary Prevention Study Group . Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) . Circulation . 1998;97:1440–1445
  24. Keech A , Colquhoun D , Best J , et al.   Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose (results from the LIPID trial) . Diabetes Care . 2003;26:2713–2721
  25. Sever PS , Dahlöf B , Poulter NR , et al.   Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA) (a multicentre randomised controlled trial) . Lancet . 2003;361:1149–1158
  26. Collins R , Armitage J , Parish S , et al.   MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes (a randomised placebo-controlled trial) . Lancet . 2003;361:2005–2016
  27. Yusuf S , Sleight P , Pogue J . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients . N Engl J Med . 2000;342:145–153
  28. The ALLHAT Officers and Coordinators . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic . JAMA . 2002;288:2981–2997
  29. Dahlöf B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol) . Lancet . 2002;359:995–1003
  30. Pfeffer MA , Swedberg K , Granger CB , et al.   Effects of candesartan on mortality and morbidity in patients with chronic heart failure (the CHARM-Overall programme) . Lancet . 2003;362:759–766
  31. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (the VALUE randomised trial) . Lancet . 2004;363:2022–2031
  32. Hansson L , Lindholm LH , Niskanen L , et al.   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension (the Captopril Prevention Project (CAPPP) randomised trial) . Lancet . 1999;353:611–616
  33. Reneland R , Alvarez E , Andersson PE , et al.   Induction of insulin resistance by beta-blockade but not ACE-inhibition (long-term treatment with atenolol or trandolapril) . J Hum Hypertens . 2000;14:175–180
  34. Olsen MH , Fossum E , Hoieggen A . Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension (ICARUS, a LIFE substudy) . J Hypertens . 2005;23:891–898
  35. Gerstein HC , Yusuf S , Holman R , et al.   Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention (the DREAM trial) . Diabetologia . 2004;47:1519–1527
  36. Teo K , Yusuf S , Anderson C , et al.   Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease. (ONTARGET/TRANSCEND) trials) . Am Heart J . 2004;148:52–61
  37. Dykewicz MS . Cough and angioedema from angiotensin-converting enzyme inhibitors (new insights into mechanisms and management) . Curr Opin Allergy Clin Immunol . 2004;4:267–270
  38. Teo KK , Yusuf S , Ramos B . Importance of an oral glucose tolerance test in identifying high prevalence of dysglycemia in individuals at high cardiovascular risk . J Am Coll Cardiol . 2005;43(suppl 1):A211; Abstract 1128-1200

 This study was supported by a grant from Boehringer Ingelheim.

PII: S0002-9343(06)00099-4

doi: 10.1016/j.amjmed.2006.01.008

The American Journal of Medicine
Volume 119, Issue 5, Supplement 1 , Pages S3-S9 , May 2006

Article Tools

* Image Usage & Resolution